KPRX Kiora Pharmaceuticals, Inc.
Company Updates ·
Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027.
Kiora named Keith J. Lane, previously Chief Scientific Officer at Ora, Inc., to lead clinical development and regulatory affairs. The appointment supports the KIO-301 retinitis pigmentosa program.
Kiora will receive a $1 million upfront payment from Chong Kun Dang for KIO-301 rights in South Korea. Kiora says its partners will coordinate a single global Phase 3 trial in retinitis pigmentosa.
Kiora ended the quarter with about $16.8 million in cash and short-term investments. The company also reported a private placement for up to $24.0 million, with $5.0 million received upfront.
KIO-300 significantly suppressed seizure-associated activity in an ex vivo mouse temporal lobe epilepsy model, Kiora said. The poster was presented at the Epilepsy Foundation Pipeline Conference on June 18-19, 2026.
Kiora ended the first quarter with $13.9 million in cash and short-term investments. It raised an additional $5.0 million in gross proceeds from a strategic equity investment after quarter end.
Kiora Pharmaceuticals, Inc. closed the deal with Perceptive Advisors and ADAR1 Capital Management on April 6, 2026, with $5.0 million in upfront funding. Up to $19 million more could come if milestone-based warrants are exercised.
Kiora said Eric J. Daniels, M.D., MBA, will leave his role as Chief Development Officer on April 17, 2026, and that the company has started a search for a successor. The company's ABACUS-2 and KLARITY trials continue.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $16.0 million |
| Research and development | $10.8 million | $7.8 million |
| Net income (loss) | -$10.8 million | $3.6 million |
| Cash from operations | -$10.0 million | $8.6 million |
| Cash and equivalents | $8.7 million | $3.8 million |
| Short-term investments | $8.4 million | $23.0 million |
Our latest story on this, dated Aug 7, 2026: "Kiora reports second quarter 2026 results and cash runway into late 2028". The story links the filing or release it is based on. Read the story.
Kiora Pharmaceuticals, Inc. trades under the ticker KPRX on NASDAQ.
Kiora Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Kiora Pharmaceuticals, Inc. is 1372514. Its filings are on SEC EDGAR.
4,424,387 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07.
Our directory records Kiora Pharmaceuticals, Inc. under United States.
Our directory classifies Kiora Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kiora Pharmaceuticals, Inc. is US49721T5074.
aibio.space lists Kiora Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Kiora Pharmaceuticals, Inc. reported a net loss of $10.8 million for the fiscal year ended Dec 31, 2025, and used $10.0 million of cash in operations, per its annual report to the SEC.
$10.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$16.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Kiora Pharmaceuticals, dated Oct 29, 2026: "Kiora in-licenses late-stage KIO-401 for retinal artery occlusion". Kiora will pay $3.5 million upfront for exclusive rights outside Asia to KIO-401 from Senju Pharmaceutical. The company plans a multinational Phase 3 trial in CRAO, targeted to start in 2027. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio